top of page
CONNECT
Let science do the talking
HOME
Our Approach
Leadership
Advisors
CSR
Academic Alliances
Licensing & Partnership
SCIENCE
Immune Oncology
Acetate Metabolism
Runaway Immune Response
Vaccine Adjuvants
Neuroinflammation
RESEARCH
Current Programs
Pipeline
Our Publications
NEWSROOM
CAREERS
CONTACT US
More
Use tab to navigate through the menu items.
O
ur
P
ipeline
HPK1 Inhibitor
Oncology
Mechanism
Indication
Discovery
Candidate
Pre-clinical
Phase I
CLK Inhibitor
Osteoarthritis
Oncology
CRD3874-SI
STING Agonist
Vaccine Adjuvant
Actinic keratosis, warts
STING Antagonist
Inflammation
bottom of page
